---

Staphylococcus aureus

---

Microbiology

• Catalase-positive (distinguishes from Streptococcus/Enterococcus)
• Coagulase-positive (the defining feature separating it from coagulase-negative staphylococci)
• Protein A expression on the cell surface
• Colonies may appear yellow/gold due to carotenoid pigments (hence "aureus" = golden)
• Grows across a wide range of conditions: aerobic and anaerobic, 18-40°C, up to 10% NaCl
• Medical Microbiology 9e

---

Epidemiology

• Atopic dermatitis, eczema, chronic skin ulcers
• Insulin-dependent diabetes
• Patients on dialysis
• HIV infection
• Injection drug users
• Patients with intravascular catheters, prosthetic devices, or surgical wounds

• Goldman-Cecil Medicine, p. 3018-3020

---

Virulence Factors

• Medical Microbiology 9e; Goldman-Cecil Medicine

---

Clinical Diseases

Toxin-Mediated Diseases

Pyogenic (Suppurative) Infections

• Skin & Soft Tissue: Impetigo, folliculitis, furuncles (boils), carbuncles, wound infections, cellulitis, necrotizing fasciitis, pyomyositis
• Bacteremia: Primary source is often an intravascular catheter or skin infection; high mortality
• Endocarditis: Both native valve (especially tricuspid in IV drug users) and prosthetic valve; aggressive, destructive course
• Pneumonia: Consolidation, abscess formation; seen in very young, elderly, post-influenza patients; necrotizing pneumonia with septic shock (often PVL-positive MRSA) carries very high mortality
• Osteomyelitis: Hematogenous spread; primarily affects metaphysis of long bones in children
• Septic arthritis: Purulent joint effusion with pain and erythema
• Meningitis: Typically device-associated (shunts)
• Empyema
• Medical Microbiology 9e; Goldman-Cecil Medicine

---

Diagnosis

• Medical Microbiology 9e; Tietz Textbook of Laboratory Medicine

---

Antibiotic Resistance: MRSA

---

Treatment

MSSA (Methicillin-Susceptible S. aureus)

• Drug of choice: Antistaphylococcal penicillins (nafcillin, oxacillin) or cefazolin (equivalent efficacy, easier dosing - supported by recent 2025 meta-analysis [PMID 40349971])
• For penicillin allergy: cefazolin (unless anaphylaxis history), vancomycin

MRSA

• For food poisoning: symptomatic treatment only (toxin pre-formed in food; antibiotics not indicated)
• Localized infections (abscesses): Incision and drainage is the primary intervention; antibiotics for systemic disease
• A 2025 meta-analysis found oral antibiotic therapy is non-inferior to IV therapy for stable S. aureus bacteremia in select patients [PMID 39290168]
• Medical Microbiology 9e; Goldman-Cecil Medicine; Harrison's Principles 22E

---

Prevention & Control

• Thorough hand hygiene (the cornerstone of hospital infection control)
• Contact precautions for MRSA-colonized/infected patients
• Proper wound care and disinfection
• Decolonization with intranasal mupirocin ± chlorhexidine bathing in high-risk patients (pre-surgical, dialysis, recurrent infections)
• Screening and isolation protocols in healthcare settings
• No approved S. aureus vaccine is currently in widespread clinical use

---

Recent Evidence Updates (2024-2025)

• Cefazolin vs. antistaphylococcal penicillins for MSSA bacteremia: A 2025 systematic review/meta-analysis (PMID 40349971) supports cefazolin as at least equivalent to oxacillin/nafcillin for MSSA bacteremia, with a potentially better safety profile.
• Oral step-down therapy for bacteremia: A 2025 meta-analysis (PMID 39290168) found oral antibiotics non-inferior to IV therapy for S. aureus bacteremia/endocarditis in stable patients meeting criteria for de-escalation, suggesting oral step-down is a viable strategy.
• MRSA comparative treatments: A 2024 network meta-analysis (PMID 38789000) compared six antibiotics for MRSA infections.

---

---

Clinical Importance of Staphylococcus aureus in ENT

---

1. The Ear

Acute Otitis Externa (AOE)

• Presents with rapid onset otalgia (worsened with pinna manipulation), pruritus, canal erythema, edema, and seropurulent discharge
• Progresses from pruritus with scant clear discharge to severe pain, canal occlusion, and conductive hearing loss
• Risk factors: swimming ("swimmer's ear"), narrow canals, eczema, seborrhea, ear plugs, hearing aid trauma, cerumen removal attempts

• Cummings Otolaryngology Head and Neck Surgery

---

Chronic Otitis Externa (COE)

• Cummings Otolaryngology

---

Necrotizing (Malignant) Otitis Externa

• Seen in diabetics, immunocompromised patients, and the elderly
• Infection spreads from the EAC into the surrounding soft tissues, cartilage, and bone, leading to osteomyelitis of the temporal bone and skull base
• Complications include cranial nerve palsies (CN VII most common), intracranial spread, meningitis, and death
• CT scanning demonstrates bony erosion
• Treatment: systemic antibiotics active against causative organism (ciprofloxacin for Pseudomonas; vancomycin for MRSA); surgical debridement in refractory cases
• Rosen's Emergency Medicine; Tintinalli's Emergency Medicine

---

Chronic Suppurative Otitis Media (CSOM)

---

Mastoiditis

• Rosen's Emergency Medicine

---

2. The Nose and Paranasal Sinuses

Nasal Colonization - The Reservoir

• Carriers have several-fold higher risk of developing S. aureus infection
• The nares serve as the source for autogenous infection (skin/soft tissue, surgical sites)
• Nasal carriage of S. aureus is associated with atopic dermatitis, eczema, and chronic skin conditions

Nasal Vestibulitis

Chronic Rhinosinusitis (CRS)

• Goldman-Cecil Medicine; Murray & Nadel's Textbook of Respiratory Medicine; Cummings Otolaryngology

Nasal Septal Abscess

---

3. The Throat, Tonsils, and Pharynx

Peritonsillar Abscess (PTA)

• Begins as acute exudative tonsillitis progressing to cellulitis and abscess
• Presents with severe throat pain, trismus, "hot-potato" voice, uvular deviation
• Treatment: needle aspiration or I&D + antibiotics covering streptococci, S. aureus, and anaerobes; tonsillectomy if recurrent
• Pfenninger and Fowler's Procedures for Primary Care

Deep Neck Space Infections

---

4. Post-Surgical ENT Infections

• Patients with known nasal MRSA carriage (identified on pre-op screening)
• Healthcare workers and their contacts
• Revision surgeries

---

5. MRSA - Special ENT Considerations

---

Summary Table: S. aureus in ENT

---

---

Clinical Importance of Staphylococcus aureus in ENT

---

THE EAR

Acute Otitis Externa (AOE) - "Swimmer's Ear"

• S. aureus is the 2nd/3rd most common bacterial isolate (after Pseudomonas aeruginosa); bacterial infections cause >90% of AOE cases
• Presents with rapid-onset otalgia worsened by pinna manipulation, canal erythema, edema, seropurulent discharge, and conductive hearing loss
• Risk factors: water exposure, narrow canals, eczema, hearing aids, cotton swab trauma
• Treatment: Topical fluoroquinolone drops (first-line); oral antibiotics are NOT effective for uncomplicated OE; aminoglycoside drops are contraindicated if TM is perforated

Chronic Otitis Externa (COE)

• Staphylococcal species (alongside Pseudomonas) are frequently cultured
• Contributes to granulation tissue, canal lichenification, and stenosis
• COE is bilateral in >50% of patients and affects 3-5% of the population

Necrotizing (Malignant) Otitis Externa

• Pseudomonas aeruginosa is the primary pathogen, but S. aureus (including MRSA) is an important alternative/co-pathogen
• Aggressive, life-threatening skull base osteomyelitis
• Seen almost exclusively in diabetics, immunocompromised, and elderly patients
• Complications: CN VII palsy (most common), meningitis, intracranial spread, death
• Diagnosis: CT showing bony erosion of temporal bone/skull base
• Treatment: Systemic antibiotics (vancomycin for MRSA); surgical debridement in refractory cases; co-management with ENT

Chronic Suppurative Otitis Media (CSOM)

• S. aureus is a recognized pathogen in persistent otorrhea through a perforated TM, alongside Pseudomonas and anaerobes
• MRSA is an emerging concern in treatment-resistant CSOM
• Often associated with cholesteatoma and middle ear destruction

Mastoiditis

• S. aureus is one of the key organisms in acute mastoiditis - the most common suppurative complication of otitis media
• Presents with postauricular erythema, tenderness, auricle protrusion, abnormal TM
• Treatment: Vancomycin IV empirically (covers MRSA); add anti-Pseudomonal coverage if previously antibiotic-treated; CT if intracranial involvement suspected; ENT consultation mandatory

---

THE NOSE AND PARANASAL SINUSES

Nasal Colonization - The ENT Reservoir

• The anterior nares are the primary ecological niche of S. aureus in humans
• ~20-30% of the general population are persistent nasal carriers
• ENT relevance:
  • Carriers have several-fold higher risk of developing invasive S. aureus infection
  • Nares serve as the autogenous source for surgical site infections
  • Higher carriage rates in atopic dermatitis, eczema, and chronic sinusitis patients

Nasal Vestibulitis

• S. aureus is the primary causative organism
• Presents as erythema, crusting, and painful furuncles at the nasal entrance
• Risk factors: nose picking, nasal hair removal, nasal cannula use
• Treatment: Topical mupirocin 2%; systemic antibiotics for spreading cellulitis or recurrent disease

Nasal Septal Abscess

• S. aureus is the most common pathogen
• Complication of nasal trauma or untreated septal hematoma
• If untreated: septal cartilage necrosis → saddle-nose deformity
• Risk of intracranial spread (cavernous sinus thrombosis, meningitis)
• Treatment: Urgent surgical drainage + antibiotics

Chronic Rhinosinusitis (CRS) - A Multifaceted Role

The S. aureus enterotoxin-superantigen mechanism is now recognized as a key driver in the pathogenesis of severe CRSwNP and comorbid asthma, making it a therapeutic target (e.g., anti-IgE therapy with omalizumab).

---

THE THROAT, TONSILS, AND PHARYNX

Peritonsillar Abscess (PTA)

• PTA is polymicrobial; S. aureus is one of the most common aerobic organisms alongside Streptococcus pyogenes (GAS); anaerobes include Bacteroides and Fusobacterium
• Progresses from acute tonsillitis → peritonsillar cellulitis → abscess
• Presents with severe odynophagia, trismus, "hot-potato" voice, uvular deviation to contralateral side
• Treatment: Needle aspiration or I&D (definitive) + antibiotics covering GAS, S. aureus, and anaerobes (amoxicillin-clavulanate or clindamycin; vancomycin if MRSA suspected)

Acute Epiglottitis

• While H. influenzae type b was historically the dominant pathogen, S. aureus (including MRSA) is now one of the important causes of adult epiglottitis in the post-Hib vaccine era
• Presents with dysphagia, drooling, muffled voice, and respiratory distress - a potential airway emergency
• Empirical antibiotics must cover S. aureus

Tonsillitis and Pharyngitis

• S. aureus contributes to recurrent and chronic tonsillitis, particularly in adults
• Found as part of the polymicrobial flora in tonsillar crypts

---

DEEP NECK SPACE INFECTIONS

---

POST-SURGICAL ENT INFECTIONS

---

MRSA - Specific ENT Considerations

---

Summary: S. aureus Across ENT

---

---

Total Ossicular Reconstruction Prosthesis (TORP) and Partial Ossicular Reconstruction Prosthesis (PORP)

---

Definitions

• Scott-Brown's Otorhinolaryngology Head & Neck Surgery; Shambaugh Surgery of the Ear

---

Anatomy of the Normal Ossicular Chain (Why Reconstruction is Needed)

---

Ossicular Defect Classification (Austin/Kartush)

The most commonly encountered ossicular defect is Type A (erosion of the long process of the incus with intact malleus and stapes), followed by types B, C, and D.

• Shambaugh Surgery of the Ear

---

How Each Prosthesis Works

PORP

• Sits with its base (cup/platform) on the stapes head (capitulum)
• Its shaft/head contacts the underside of the TM or the medial surface of the malleus manubrium
• Transmits vibrations: TM → PORP → stapes capitulum → stapes footplate → oval window → cochlea
• Effective length: typically ~2.0-2.5 mm

TORP

• Sits with its base directly on the stapes footplate
• Its shaft/head contacts the underside of the TM or malleus
• Used when the stapes crura are destroyed (e.g., by cholesteatoma, chronic OM, trauma)
• Effective length: typically ~3.5-4.5 mm (longer than PORP as it spans greater distance)
• Generally achieves slightly poorer hearing results than PORP due to the longer lever arm and absence of the stapes superstructure's natural amplification

---

Materials Used

1. Plastipore (High-Density Polyethylene Sponge - HDPS)

• First dedicated PORP and TORP (Sheehy, 1976)
• Porous structure encourages tissue ingrowth (fibrocytes, small round cells)
• Extrusion rates: 3-5% over 5-10 years (most within first year)
• Requires cartilage interposition to minimize extrusion
• Still used widely; preferred by ~16% of US otologists in surveys
• Shambaugh Surgery of the Ear

2. Hydroxylapatite (HA)

• Bioactive calcium phosphate material chemically similar to bone
• Promotes osseointegration - direct bone contact with the implant
• Excellent biocompatibility; minimal reactive fibrosis; can tolerate direct TM contact
• However, extrusion with thin TM reported in ~16% if no cartilage interposition
• Can fracture during trimming due to brittleness; use a diamond burr with copious irrigation
• Available in dense and porous forms; preferred by ~48% of US otologists
• Shambaugh Surgery of the Ear

3. Titanium

• Introduced by Stupp in 1993
• Lightweight, strong, excellent biocompatibility, tendency to osseointegrate
• Allows laser-cut precision designs (e.g., self-securing clips, complex cup designs)
• Can be MRI-compatible (non-ferromagnetic grades)
• Does extrude when in direct contact with TM - cartilage interposition is mandatory
• Now one of the two most commonly used materials (alongside HA)
• Shambaugh Surgery of the Ear

4. Other/Historical Materials

---

Surgical Principles: The TRACS Mnemonic

---

Cartilage Interposition - Why It Matters

• Reduces extrusion risk - the most important complication of ossiculoplasty
• Augments the prosthesis-tissue interface for better long-term hearing
• Particularly essential with titanium and in thin/atrophic TMs
• Can be partial or full thickness
• Also indicated in: revision surgery, perforations >50%, drainage at surgery, bilateral perforations, post-cholesteatoma reconstruction
• Cummings Otolaryngology

---

Hearing Outcomes

1. The longer column is more susceptible to displacement
2. Loss of the stapes superstructure removes natural lever amplification
3. Footplate contact is technically more demanding

• Eustachian tube dysfunction (atelectasis, negative middle ear pressure)
• Active middle ear infection at the time of surgery
• Absence of malleus (no support for prosthesis)
• Thin/atrophic TM
• Revision surgery
• Cummings Otolaryngology; Shambaugh Surgery of the Ear

---

Complications

---

Surgical Timing and Staging

1. Stage 1: Disease removal (cholesteatoma, granulation tissue) + TM repair; a Silastic sheet or cartilage may be placed over the footplate to maintain middle ear space
2. Stage 2 (6-12 months later): Ossiculoplasty with PORP/TORP once the middle ear is healed, dry, and well-aerated

---

Recent Developments (2024-2025)

• TORP-PORP hybrid technique (PMID 38361297, Otol Neurotol 2024): A novel technique for isolated stapes suprastructure defects where a TORP is modified to function as a PORP - addressing the Austin Type A defect when stapes superstructure is partially destroyed
• Bone vs titanium prostheses (PMID 38932647, Clin Otolaryngol 2024): A nationwide register-based study found similar hearing outcomes between autologous bone and titanium prostheses
• Long-term ossiculoplasty outcomes (PMID 40567078, Acta Otolaryngol 2025): Long-term data continues to support titanium as a durable option with good hearing gains

---

Quick Reference Summary

PORP: Stapes head → PORP → TM (stapes superstructure INTACT)
TORP: Stapes footplate → TORP → TM (stapes superstructure ABSENT)

Materials: Titanium (most common) | Hydroxylapatite | Plastipore
Key step: ALWAYS place cartilage between prosthesis head and TM
Goal: Air-bone gap < 20 dB postoperatively
TRACS: Tension | Round window | Angle | Centered | Space

---

---

TORP and PORP - Ossicular Reconstruction Prostheses

---

Core Definitions

---

Background and History

• Normal ossicular chain (malleus - incus - stapes) provides ~27 dB of mechanical gain; disruption causes conductive hearing loss of 40-60 dB
• The long process of the incus is the most commonly eroded ossicle (poor blood supply; most vulnerable to chronic OM and cholesteatoma)
• Wullstein (1952) first classified tympanoplasty types I-V based on ossicular status
• Sheehy (1976) introduced the first dedicated PORP and TORP made from Plastipore (high-density polyethylene sponge)
• The terms TORP/PORP were popularized by Brackmann and Sheehy in their landmark 1979 paper (Laryngoscope)

---

Ossicular Defect Classification (Austin/Kartush)

---

Wullstein Tympanoplasty Classification (Relevant to Prosthesis Selection)

Type III tympanoplasty with a PORP or TORP is the most commonly performed ossiculoplasty today.

---

PORP - Detailed

When to Use

• Stapes superstructure (head + crura) is intact
• Malleus may or may not be present
• Incus is absent or non-functional

Mechanism

Tympanic Membrane → PORP head → PORP shaft → cup on stapes capitulum → footplate → oval window → cochlea

Dimensions

• Typical length: ~2.0-2.5 mm
• The cup/platform base engages the stapes capitulum
• Head contacts TM (preferably with cartilage cap interposed)

Hearing Results

• Air-bone gap closure to within 20 dB in approximately 60-70% of cases
• Better results when malleus is preserved (prosthesis angulation is more favorable)

---

TORP - Detailed

When to Use

• Stapes superstructure is absent (destroyed by cholesteatoma, chronic OM, trauma, or surgery)
• Only the stapes footplate remains
• Malleus may or may not be present

Mechanism

Tympanic Membrane → TORP head → TORP shaft → base on stapes footplate → oval window → cochlea

Dimensions

• Typical length: ~3.5-4.5 mm (longer than PORP to reach footplate)
• Base must be stable and centered on the footplate (not on annular ligament)

Hearing Results

• Air-bone gap closure to within 20 dB in approximately 40-55% of cases
• Less predictable than PORP due to:
  • Longer lever arm = more displacement risk
  • Loss of natural stapes superstructure amplification
  • Footplate contact technically more demanding
  • Risk of perilymph fistula from excessive footplate pressure

---

Prosthesis Materials

1. Plastipore (HDPS - High-Density Polyethylene Sponge)

• First material used (Sheehy, 1976)
• Porous structure allows fibrous tissue ingrowth
• Biocompatible, non-reactive
• Extrusion rate: 3-5% at 5-10 years (most in year 1)
• Cartilage cap mandatory to reduce extrusion
• Still preferred by ~16% of US otologists

2. Hydroxylapatite (HA)

• Calcium phosphate composition similar to bone; bioactive
• Promotes osseointegration; minimal reactive fibrosis
• Most biocompatible material for TM contact
• Extrusion rate with thin TM if no cartilage: up to 16%
• Brittle - trim carefully with diamond burr + copious irrigation
• Preferred by ~48% of US otologists (most popular overall)
• Available in dense and porous forms

3. Titanium

• Introduced by Stupp, 1993
• Lightweight, strong, precise (laser-cut designs possible)
• Excellent biocompatibility; osseointegrates
• Self-securing clip designs improve intraoperative stability
• MRI-compatible (non-ferromagnetic)
• Extrudes without cartilage - cartilage interposition is mandatory
• Now one of the two most commonly used materials (alongside HA)

4. Other Materials (Historical/Adjunctive)

---

Cartilage Interposition - The Critical Step

• Reduces extrusion (the most important long-term complication)
• Provides structural support to thin or atrophic TM
• Improves long-term stability of prosthesis-TM interface
• Especially essential with titanium (mandatory) and in high-risk TMs

• Thin, atrophic, or retracted TMs
• Titanium prostheses (all cases)
• Revision surgery
• Perforation >50% of TM
• Discharge present at time of surgery
• Post-cholesteatoma reconstruction
• Bilateral perforations

---

The TRACS Principles (Surgical Biomechanics)

---

Indications for Ossiculoplasty

• Chronic otitis media with ossicular erosion (most common)
• Cholesteatoma surgery (staged or single-stage)
• Traumatic ossicular disruption (incudostapedial joint dislocation, incus dislocation)
• Tympanosclerosis with ossicular fixation
• Congenital ossicular anomalies
• Failed previous ossiculoplasty

• Dry ear (no active infection) for at least 3 months (or staged approach)
• Adequate Eustachian tube function (or plan for tympanostomy tube)
• Conductive hearing loss >30 dB ABG
• Contralateral ear hearing adequate enough to make surgery meaningful

---

Surgical Staging

Single-stage ossiculoplasty

• Disease removal + ossicular reconstruction at one operation
• Appropriate when: limited disease, dry ear, good ET function, intact TM

Two-stage ossiculoplasty (preferred for cholesteatoma / complex disease)

• Stage 1: Remove disease, repair TM; place Silastic sheet or cartilage to maintain middle ear space; may place a "blind" PORP/TORP under the cartilage
• Stage 2 (6-12 months later): Second-look for residual cholesteatoma + formal ossiculoplasty in a healed, well-aerated middle ear

---

Hearing Outcome Benchmarks

• Active middle ear infection / wet ear
• Eustachian tube dysfunction / atelectasis
• Absent malleus (no support)
• Thin / atrophic TM
• Revision surgery
• Presence of cholesteatoma matrix

---

Complications

---

Quick Reference

PORP  →  Stapes superstructure INTACT  →  Head on stapes capitulum
TORP  →  Stapes superstructure ABSENT  →  Base on stapes footplate

Best material:  Titanium or Hydroxylapatite
Always use:     Cartilage cap between prosthesis and TM
Best results:   Traumatic IS joint dislocation (78% within 10 dB)
PORP > TORP in hearing outcomes
Goal:           ABG < 20 dB postoperatively
Mnemonic:       TRACS (Tension, Round window, Angle, Centered, Space)

---

---

Virtual Endoscopy in ENT

---

Definition and Concept

1. Thin-section volumetric CT (or MRI) data is acquired
2. DICOM data is processed using specialized software (e.g., OsiriX, 3D Slicer, Syngo.via, Voxar 3D)
3. Surface rendering or volume rendering algorithms generate a photorealistic intraluminal view
4. The virtual camera is navigated ("flown") through the airway or cavity

"Virtual endoscopy is a computer-generated simulation of endoscopic perspective. The virtual endoscopic images of the trachea, larynx, pharynx, nasal cavity, paranasal sinuses, and ear have demonstrated clinical utility."

• Cummings Otolaryngology Head and Neck Surgery

---

Technical Basis

Imaging Modalities Used

Software Processing Steps

1. Segmentation - identify the target hollow structure by thresholding (e.g., air density -1000 to -500 HU)
2. Surface/volume rendering - generate a 3D model of the internal lumen surface
3. Path planning - define a virtual camera flight path through the lumen
4. Navigation - automated or manual fly-through with real-time rendering
5. Correlation - simultaneous display of VE view with axial/coronal/sagittal 2D images

---

ENT Applications - By Region

1. Nasal Cavity and Paranasal Sinuses

• Pre-operative planning for Functional Endoscopic Sinus Surgery (FESS) - visualize sinus ostia, uncinate process, ethmoid labyrinth, and critical landmarks before actual endoscopy
• Evaluation of chronic rhinosinusitis and extent of sinonasal disease
• Assessment of nasal polyps and their extent into posterior sinuses
• Detection of sinonasal tumors - define extent, relationship to orbit, skull base, and cribriform plate
• Choanal atresia - evaluate patency and type (bony vs membranous) without instrumentation (especially useful in neonates)
• Assessment after prior surgery (anatomical distortion makes physical endoscopy harder to interpret)

• Can visualize areas inaccessible to conventional endoscopy (e.g., frontal recess, posterior ethmoids, sphenoid sinus)
• Overcomes patient discomfort/non-cooperation (especially pediatric patients)
• No risk of mucosal trauma or epistaxis
• Can be performed retrograde (from posterior to anterior)

• Cummings Otolaryngology

---

2. Larynx and Trachea (Virtual Laryngoscopy / Virtual Bronchoscopy)

• Laryngotracheal stenosis (LTS): CT with multiplanar reconstruction and VE is "highly accurate for detecting LTS" - can define the level (supraglottis, glottis, subglottis, trachea), length, and degree of stenosis for preoperative planning (Radiographics 2025, PMID 40638414)
• Laryngeal tumors: Assess subglottic extension, transglottic spread, and relationship to cartilage; plan partial laryngectomy vs total laryngectomy
• Post-intubation/post-tracheostomy stenosis: Quantify severity and plan dilation, resection, or stenting
• Foreign body (especially in children): Localise position before removal
• Vocal cord pathology: Adjunctive to conventional laryngoscopy; especially when airway is critically compromised and direct laryngoscopy is risky
• Congenital airway anomalies: Subglottic hemangioma, congenital subglottic stenosis, vascular rings

VE is particularly valuable for evaluating the airway distal to a stenosis - a region that may be completely inaccessible to direct endoscopy but is critical for surgical planning.

---

3. The Ear - Temporal Bone Virtual Endoscopy

• Assess stenosis (canal atresia, inflammatory stenosis)
• Evaluate extent of canal cholesteatoma

• Virtual otoscopy of the tympanic membrane
• Assess ossicular chain integrity (especially useful in congenital anomalies)
• Planning for cochlear implantation: A 2026 prospective study (PMID 41264375, Otol Neurotol) used CT-based VE to predict round window (RW) accessibility during cochlear implant surgery - achieving 96% accuracy with excellent inter-rater reliability (ICC 0.971). Virtual posterior tympanotomy and mastoidectomy were simulated using OsiriX software on DICOM data. This is now considered a valid, reliable, and reproducible preoperative tool.
• Assess anatomical variants relevant to surgery: high jugular bulb, aberrant ICA, dehiscent facial nerve canal

• Virtual endoscopy of the cochlea and semicircular canals (using ultra-thin CT or MRI)
• Planning electrode insertion for cochlear implants
• Visualize cochlear malformations (Mondini, incomplete partition, common cavity)

---

4. Skull Base and Deep Neck

• Map extent of skull base tumors (glomus jugulare, acoustic neuroma, chordoma)
• Evaluate relationship of tumor to ICA, jugular vein, facial nerve
• Plan endoscopic skull base surgery approaches (transsphenoidal, transnasal, transpterygoid corridors)
• Assess post-treatment anatomy and recurrence

---

5. Head and Neck Oncology

• Nasopharynx: Evaluate nasopharyngeal carcinoma extent; assess skull base invasion
• Oropharynx/hypopharynx: Assess tumor margins, pyriform fossa extension, cricopharyngeus
• Salivary duct VE (virtual sialendoscopy): CT or MRI-based visualization of parotid and submandibular ducts for sialolithiasis and stenosis - adjunct to actual sialendoscopy

---

Advantages of Virtual Endoscopy in ENT

---

Limitations of Virtual Endoscopy

---

Comparison: Virtual Endoscopy vs. Conventional Endoscopy

---

Recent Advances (2024-2026)

---

Clinical Workflow Example: VE for Pre-FESS Planning

1. Obtain thin-section CT sinuses (coronal + axial, <1 mm slices, no contrast)
2. Load DICOM data into VE workstation (OsiriX, Syngo.via, etc.)
3. Segment air-filled nasal cavity and sinuses
4. Navigate virtual camera from nasal vestibule → choana:
   - Assess inferior turbinate, middle meatus, uncinate process
   - Identify and grade ostiomeatal complex obstruction
   - Visualize frontal recess anatomy (agger nasi cells, frontal cells)
   - Assess maxillary, ethmoid, sphenoid ostia
5. Correlate each VE view with corresponding 2D CT slice
6. Document anatomical variants (Onodi cell, Haller cell, paradoxical turbinate,
   Keros classification of cribriform plate depth)
7. Use same CT dataset for intraoperative navigation (IGS) during FESS

---

Summary

• Pre-surgical planning for FESS, laryngotracheal reconstruction, and cochlear implantation
• Assessment of stenoses and obstructions inaccessible to conventional endoscopy
• Pediatric ENT where physical endoscopy is difficult
• Skull base surgery where 3D spatial orientation is critical
• Teaching and simulation

---

---

Optical Coherence Tomography (OCT) and Its Uses in ENT

---

What is OCT?

"OCT is an analogue of ultrasound, using light instead of sound to produce a high (micrometre) resolution cross-sectional image, similar to a vertical histological section."

• Scott-Brown's Otorhinolaryngology Head & Neck Surgery

---

Physical Principles

How OCT Works

OCT System Types

---

OCT Characteristics Relevant to ENT

---

ENT Applications

1. THE EAR - Most Clinically Developed ENT Application

A. Tympanic Membrane (TM) Imaging

• TM layers (epithelial, fibrous, mucosal layers)
• TM thickness measurement
• Myringosclerosis and tympanosclerosis plaques (depth and extent)
• Perforations and their margins
• Retraction pockets and their depth
• Cholesteatoma vs. serous effusion behind an intact TM

B. Middle Ear Effusion - Otitis Media

• Non-invasively visualize and characterize MEEs (serous vs. mucoid vs. purulent) based on optical backscattering
• Detect TM-adherent biofilms - a 2023 observational study (PMID 37253962) of 53 pediatric OM patients showed 89.6% had TM-adherent biofilm visible on OCT prior to tube surgery; this correlated with surgical findings
• Quantify MEE characteristics (viscosity, depth) that correlate with surgical outcome
• Distinguish otitis media with effusion (OME/"glue ear") from acute OM without tympanotomy
• Guide timing of tympanostomy tube insertion

C. OCT-Vibrometry - Middle and Inner Ear Mechanics

• Measure TM, ossicular chain, and round window vibration amplitudes and phases
• Map basilar membrane mechanics within the cochlea
• Quantify the functional impact of ossicular pathology (fixation, discontinuity)
• Assess stapes footplate motion in otosclerosis
• Evaluate cochlear partition mechanics in sensorineural hearing loss research

"OCT can be used as a vibrometry system capable of detecting sound-induced sub-nanometer vibrations of the middle and inner ear... the largest clinical impact of OCT for otology is to visualize various pathologies and quantify sound conduction and processing in the individual peripheral human ear."

• Seminars in Hearing 2024 (PMID 38370517)

D. Cholesteatoma Assessment

• Distinguish cholesteatoma keratin matrix from granulation tissue and effusion
• Assess depth of invasion into the mesotympanum
• A 2025 JAMA Otolaryngology study (PMID 40178817) fused middle ear OCT with CT images using rigid coregistration - finding that OCT revealed soft tissue features (e.g., cholesteatoma margins, traumatic middle ear injury detail) not apparent on CT, while CT provided superior bony overview; the two modalities were complementary

E. Cochlear Implant Surgery - A Major Emerging Application

1. Pre-insertion planning: OCT-based atlas of the cochlear hook region (PMID 36615042) enables detailed visualization of scala tympani dimensions and cochlear anatomy
2. Intraoperative real-time guidance: An optically-guided cochlear implant sheath integrating a fiber-optic OCT probe (PMID 36357503, Sci Rep 2022) provides real-time feedback during electrode insertion - the surgeon can detect cochlear walls (modiolar wall, osseous spiral lamina, basilar membrane) ahead of the advancing electrode and adjust trajectory in real time to prevent intracochlear trauma
3. Post-insertion verification: Transtympanic OCT can confirm electrode positioning after insertion (PMID 35970156, Otol Neurotol 2022)

---

2. THE LARYNX - Optical Biopsy for Cancer

"In combination with microlaryngoscopy, OCT has been shown to significantly increase the sensitivity of determining benign versus malignant lesions and the grade of precancerous lesions when compared to microlaryngoscopy alone. Further studies are needed, however, to determine whether the optical biopsy derived from OCT can indeed replace an excisional tissue biopsy."

• Scott-Brown's Otorhinolaryngology Head & Neck Surgery

---

3. PARANASAL SINUSES AND NASAL CAVITY

• OCT can visualize mucociliary function - measure ciliary beat frequency and mucus transport in nasal epithelium (relevant to primary ciliary dyskinesia, cystic fibrosis, post-FESS assessment)
• Sinonasal tumors: OCT can potentially assess mucosal dysplasia depth
• Nasal polyp microstructure: Distinguish edematous stroma from invasive pathology
• Currently primarily a research tool for nasal/sinus applications; not yet standard clinical practice

---

4. UPPER AIRWAY / SLEEP MEDICINE

• OCT integrated into a catheter can image the pharyngeal airway cross-sectionally during sleep or sedation
• Quantify pharyngeal collapsibility in obstructive sleep apnea (OSA)
• Map the site and degree of upper airway collapse - critical for surgical planning (UPPP, tongue base surgery, hypoglossal nerve stimulation selection)
• Distinguish velopharyngeal from oropharyngeal/hypopharyngeal obstruction sites
• This is a growing research area with clinical translation potential

---

5. HEAD AND NECK TUMORS

• Oral cavity: OCT can detect submucosal extension of oral SCC, assess depth of invasion (a key prognostic factor)
• Oropharynx: Assess tonsillar and BOT lesion depth
• Thyroid: High-frequency OCT has been studied for thyroid nodule microstructure assessment
• Salivary glands: Experimental use for detecting salivary duct lesions and gland microstructure

---

Comparison: OCT vs. Other ENT Imaging Modalities

---

OCT vs. CT - Middle Ear (JAMA Otolaryngology 2025, PMID 40178817)

---

Advantages of OCT in ENT

---

Limitations of OCT in ENT

---

Current Status by ENT Region

---

Recent Advances (2022-2025)

---

Summary

OCT = Light-based, non-invasive, µm-resolution cross-sectional tissue imaging
Principle: Interferometry measures echo time delay of reflected near-infrared light

Top ENT applications:
1. EAR:
   - TM: layers, thickness, perforation, retraction depth
   - Middle ear: effusion type, biofilm, cholesteatoma soft tissue
   - Cochlear implant: intraoperative real-time electrode guidance
   - Vibrometry: ossicular/cochlear mechanics, sub-nm vibration measurement

2. LARYNX:
   - Optical biopsy: benign vs. malignant (basement membrane integrity)
   - Grades dysplasia; guides biopsy; assesses surgical margins

3. UPPER AIRWAY: pharyngeal collapse mapping in OSA (research)
4. SINUSES: ciliary function, mucosal dysplasia (research)

Key limitation: 1-3 mm depth only; cannot replace histological biopsy
Key strength: Real-time, radiation-free, near-histological, functional vibrometry

---

---

Alar Collapse

---

Definition

---

Relevant Anatomy

The Nasal Valves

---

Pathophysiology

Bernoulli Effect and Nasal Valve Dynamics

• Negative pressure is generated in the nasal airway
• This exerts an inward force on the lateral nasal walls
• Normally, the structural rigidity of the LLC (lateral crus) resists this force
• When LLC support is insufficient, the ala is sucked inward with each breath → alar collapse

---

Classification

By Level of Collapse

Recent subclassification distinguishes the alar valve (LLC lateral crus region) from the rim valve (alar rim/lobule) to better guide surgical planning - Clin Exp Otorhinolaryngol 2024 (PMID 39111772)

By Mechanism (Dynamic vs. Static)

---

Causes

Primary (Congenital/Constitutional)

• Inherent LLC weakness - thin, floppy lateral crura that cannot resist inspiratory negative pressure
• Cephalic malposition of the LLC - an acute orientation of the LLC >35-45° off midline; the cartilage provides less lateral wall support
• Lax connective tissue (seen in aging or connective tissue disorders)
• Wide piriform aperture

Secondary (Acquired)

• Post-rhinoplasty (most common iatrogenic cause):
  • Over-resection of the LLC during cephalic trim → loss of structural support
  • Postoperative scar contracture at intercartilaginous or marginal incisions
  • Excessive tip narrowing procedures weakening lateral crural support
• Recurvature of the lateral crura - the lateral crus curves inward rather than lying flat, paradoxically directing it toward the airway
• Trauma - fracture or disruption of the LLC
• Aging - loss of connective tissue support and skin elasticity
• Facial paralysis - loss of dilator naris muscle tone (a significant contributor)
• Previous septal surgery - destabilization of the nasal base

---

Clinical Features

Symptoms

• Nasal obstruction - typically unilateral or bilateral; worse with exercise/deep breathing
• Inspiratory collapse - patient or examiner can see the ala "sucking in" on deep inspiration
• Exaggerated supra-alar crease - visible groove above the alar rim
• Mouth breathing, snoring, sleep-disordered breathing
• Reduced exercise tolerance due to nasal airway limitation
• Often associated with alar-columellar disharmony: excess columellar show (>4 mm on lateral view) and alar notching

Signs on Examination

• Visible alar collapse on deep nasal inspiration
• Exaggerated supra-alar crease
• Thin, underprojected alae
• Cephalic LLC malposition (>35-45° off midline on frontal view)
• "Parenthesis deformity" on frontal view (when combined with bulbous, cephalically oriented lateral crura)
• Alar retraction with excess columellar show (>4 mm)
• Alar notching at the apex of the alar margin

---

Diagnosis and Assessment

Clinical Tests

1. Modified Cottle Maneuver

• Gentle lateralization of the lateral nasal wall using a cotton-tipped applicator, cerumen curette, or similar instrument
• Specifically opens the internal nasal valve angle
• Positive result: Relief of nasal obstruction on lateralization = nasal valve compromise confirmed
• More specific than the classic Cottle maneuver (which moves too much tissue and gives many false positives)

"Gentle lateralization of the ULC with a cotton-tipped applicator, a cerumen curette, or similar instrument is a more specific maneuver to increase the internal nasal valve angle and, in those with a narrow angle, to improve airflow." - Cummings Otolaryngology

2. Breathe Right Strip Test

• Application of an external nasal dilator strip (Breathe Right) across the nasal dorsum
• If it significantly relieves obstruction → external nasal valve/lateral wall insufficiency

3. Dynamic Nasal Inspection

• Ask patient to breathe in forcefully through nose - observe alar collapse in real time
• Quantify degree of collapse (mild/moderate/severe)

4. Nasal Endoscopy

• Assess internal nasal valve angle, septal deviation, turbinate hypertrophy, and scarring
• Rule out concurrent causes of obstruction (polyps, adenoids, mass)

5. Objective Assessment (Research/Specialist)

• Rhinomanometry - measures nasal airflow resistance; documents functional impairment and surgical outcomes
• Acoustic rhinometry - maps cross-sectional area at each nasal level; identifies site of minimum cross-sectional area
• NOSE scale (Nasal Obstruction Symptom Evaluation) and SNOT-22 - validated patient-reported outcome measures

---

Treatment

Non-Surgical

Surgical

• Cummings Otolaryngology

1. Alar Batten Grafts

• Most commonly used graft for external nasal valve/alar collapse
• Cartilage graft (usually septal or auricular conchal cartilage) placed in a precise pocket at the area of maximal lateral wall weakness
• Overlaps slightly with the lateral crus of the LLC
• Stiffens the lateral wall, preventing inspiratory collapse
• Can correct both internal and external nasal valve collapse
• Placed via marginal or intercartilaginous incision
• Works for primary and post-rhinoplasty alar collapse

2. Lateral Crural Strut Grafts (LCSGs)

• Cartilage graft sutured to the dissected undersurface of the lateral crus, extending to the dome
• Three functions:
  1. Flatten recurvature of the lateral crus
  2. Reorient the caudal margin above the cephalic margin
  3. Provide structural support to the lateral nasal wall
• Creates a strong, well-positioned strut of the lateral crus
• Powerful technique for recurved or malpositioned lateral crura
• Can correct alar retraction by repositioning the LLC into a pocket just below the supra-alar groove (cantilever effect that lowers the nostril margin)

3. Spreader Grafts

• Cartilage grafts placed between the nasal septum and the upper lateral cartilages
• Primary indication: Internal nasal valve stenosis/narrowing
• Also used when ULC-septal junction is narrowed, contributing to upstream obstruction
• Patients with positive cotton-tip applicator lateralization test often benefit from spreader grafts

4. LLC Repositioning (Cephalic Malposition Correction)

• When the LLC is cephalically malpositioned (>35-45° off midline):
  • The LLC is detached and repositioned in a more favorable orientation
  • Simultaneously improves cosmesis (reduces parenthesis deformity) and restores functional support
  • Affects nasal length, projection, and rotation in addition to function

5. Alar Extension Graft

• A newer technique specifically for external nasal valve collapse
• Graft extends the lateral crus caudally to bolster the alar rim
• A 2025 prospective study (PMID 38992252, Aesthetic Plast Surg) of 51 patients showed:
  • 90% subjective satisfaction with nasal breathing improvement
  • Significant improvement in NOSE and SNOT-20 scores
  • Rhinomanometry showed significantly increased nasal flow post-operatively

6. Composite Auricular Grafts

• Used when significant scar contracture exists at marginal/intercartilaginous incisions (common in alar retraction)
• Auricular skin-cartilage composite graft creates tension-free closure while providing structural support

7. Caudal LLC Extension Graft

• Extends the caudal margin of the lateral crus
• Addresses alar retraction and provides lateral wall support simultaneously

Surgical Approach

Graft Donor Sites (in order of preference)

---

Alar Collapse vs. Alar Retraction - Key Distinction

---

Summary

Alar collapse = Dynamic inspiratory inward collapse of ala
               due to inadequate LLC structural support

Mechanism:   Bernoulli negative pressure overwhelms weakened lateral crura
Causes:      Congenital LLC weakness, cephalic malposition,
             post-rhinoplasty (over-resection), aging, facial paralysis, trauma

Diagnosis:   Modified Cottle/cotton-tip lateralization test (most specific)
             Observe dynamic collapse on forced inspiration
             Rhinomanometry for objective quantification

Treatment:
- Non-surgical: External nasal dilator strips, internal splints
- Surgical:
  • Alar batten graft (most common) - lateral wall support
  • Lateral crural strut graft - strut + recurvature correction
  • Spreader graft - internal nasal valve (upstream)
  • LLC repositioning - cephalic malposition
  • Alar extension graft - newer; effective (90% satisfaction)

Key principle: Restore structural rigidity to resist inspiratory
               negative pressure

---

---

Bondy's Atticotomy (Bondy's Modified Radical Mastoidectomy)

---

Historical Background

---

Position in Surgical Classification

"Surgeries that rely on exteriorization include radical mastoidectomy, modified radical mastoidectomy, and the Bondy procedure."

• Cummings Otolaryngology Head and Neck Surgery

---

The Three Key Operations - Compared

---

Definition of Bondy's Operation

1. Exenterates the mastoid air cells, antrum, and attic (epitympanum) - removing all disease and the posterior/lateral canal wall to create an open cavity
2. Preserves the mesotympanum - the tympanic membrane, ossicular chain (malleus, incus, stapes), middle ear mucosa, and Eustachian tube are left completely undisturbed
3. Creates a common cavity between the mastoid, attic, and external auditory canal
4. Seals the mesotympanum from the open cavity - the tympanic membrane and lateral attic wall remnant act as a barrier, preventing the open mastoid cavity from communicating with the functioning middle ear

---

The Critical Prerequisite

• Cholesteatoma is strictly confined to the attic, antrum, and mastoid
• The mesotympanum is normal (healthy TM, intact and functional ossicular chain, good middle ear mucosa)
• There is no cholesteatoma extension into the mesotympanum, Eustachian tube, or sinus tympani

---

Pathological Basis

How Attic Cholesteatoma Develops

• The pars flaccida (Shrapnell's membrane) - the upper, unsupported part of the TM - is prone to retraction due to chronic negative middle ear pressure (Eustachian tube dysfunction)
• The retraction pocket gradually invaginates medially into the attic (epitympanum)
• Accumulating desquamated keratin debris forms the cholesteatoma sac
• Disease expands laterally (eroding the scutum - the bony lateral wall of the attic), then posteriorly into the antrum and mastoid
• The mesotympanum may remain entirely uninvolved in early cases - this is the window of opportunity for Bondy's operation
• An attic or pars flaccida perforation always signifies cholesteatoma

Why Disease Confined to Attic?

• The scutum (lateral wall of epitympanum) and the necks of the malleus and incus form a partial anatomical barrier that can, in some cases, contain disease to the attic and mastoid without mesotympanic involvement
• Early or limited cholesteatoma respects these boundaries

---

Indications

Absolute Indication

• Attic cholesteatoma strictly limited to the epitympanum, aditus ad antrum, and mastoid, with a completely normal and intact mesotympanum

Additional Considerations

• Patients with good pre-operative hearing in whom middle ear preservation is paramount
• Where CWU (canal-wall-up) tympanomastoidectomy is technically difficult (sclerotic mastoid, limited pneumatization, low-lying tegmen)
• Patients in whom a two-stage procedure is impractical (poor compliance, geographic inaccessibility)
• Occasional or less experienced otologic surgeons for attic cholesteatoma (MRM/Bondy being technically less demanding than staged CWU)
• Only-hearing ear with attic cholesteatoma (hearing preservation of paramount importance)

---

Contraindications

• Cholesteatoma extending into the mesotympanum (then requires MRM or CWU)
• Cholesteatoma extending to the Eustachian tube orifice or petrous apex
• Extensive labyrinthine fistula (especially if matrix cannot be left safely)
• Medically unfit patients (general anaesthesia risk)
• Patients with limited attic disease who are reliable for follow-up (CWU or simple atticotomy with scutal reconstruction may suffice instead)

---

Surgical Technique

Pre-operative Setup

• General anaesthesia (with facial nerve monitoring strongly recommended)
• Patient: supine, head turned, operated ear facing upward
• Pre-operative CT temporal bone mandatory: assess extent of disease, mastoid pneumatization, integrity of tegmen and sigmoid sinus plate, semicircular canal status, facial nerve dehiscence, ossicular chain

Step-by-Step Operative Technique

• Postauricular (endaural) incision - postauricular approach gives wider access; endaural may be used for limited disease
• Elevate the skin and periosteum; expose the mastoid cortex and posterior EAC

• Drill the mastoid cortex (Macewen's triangle)
• Exenterate all mastoid air cells
• Identify the sigmoid sinus posteriorly, tegmen superiorly, and posterior semicircular canal
• Open the mastoid antrum - identify the lateral semicircular canal as the key landmark
• Follow cholesteatoma matrix forward through the aditus into the attic

• Remove the posterior and lateral bony wall of the EAC (posterior canal wall takedown)
• Remove the scutum (lateral attic wall) to expose the epitympanum
• The head of the malleus and short process of the incus (occupying the attic) are visualized
• Remove all cholesteatoma matrix from the epitympanum, around the ossicles, and from the antrum and mastoid
• The mesotympanum is NOT entered - the TM and ossicular chain below the level of the neck of the malleus are preserved and left in situ
• The area just inferior to the ossicles forms the natural boundary between the attic and mesotympanum - this is respected

• The attic, antrum, and mastoid are now a single open cavity communicating with the EAC
• The mesotympanum is sealed off by the intact TM and remaining ossicular structures
• This is the defining feature of Bondy's operation vs. full MRM

• The cavity must be smoothly contoured - no overhanging ridges, no "sump" below the floor of the EAC, no high facial ridge
• A low facial ridge is essential: the facial nerve ridge must be drilled down to the level of the fallopian canal to allow epithelialization and self-cleaning
• Round, shallow bowl configuration

• The facial (fallopian) ridge - the bony prominence overlying the facial nerve - is carefully drilled down
• A high facial ridge is the most common cause of a discharging mastoid cavity (prevents self-cleaning)
• Must be lowered to the level of the fallopian canal without injuring the facial nerve

• Mandatory - the external auditory meatus must be widened (enlarged) to allow:
  • Adequate access for post-operative cavity inspection and cleaning
  • Adequate ventilation of the cavity
  • Self-epithelialization
• The conchal cartilage removed during meatoplasty is used to partially obliterate and reduce cavity volume

• Partial obliteration with cartilage, bone pate, or abdominal fat reduces cavity volume
• Smaller cavities are easier to maintain and have better rates of self-cleaning

• Skin flap repositioned; closure in two layers; mastoid dressing applied

---

Key Anatomical Landmarks

---

Post-operative Care and Follow-up

---

Advantages of Bondy's Operation

---

Disadvantages of Bondy's Operation

---

Comparison: Bondy vs. MRM vs. CWU

---

Results

• A dry, self-cleaning mastoid cavity can be maintained in ~95% of cases with strict attention to technique (low facial ridge, adequate meatoplasty, well-saucerized cavity)
• Epithelial pearls occur in 5-6% and are usually managed in-office
• Hearing results are unchanged from pre-operative levels (preservation, not improvement)
• Canal-wall-down procedures achieve lower recurrence (2-10%) than CWU (5-13%), with residual cholesteatoma a rarity in experienced hands
• Shambaugh Surgery of the Ear; Scott-Brown's Otorhinolaryngology

---

Summary

Bondy's Atticotomy:
= Canal-wall-DOWN procedure for ATTIC-ONLY cholesteatoma
= Mastoid + attic + antrum exteriorized → open cavity
= Mesotympanum, TM, ossicles, Eustachian tube LEFT INTACT
= Hearing PRESERVED at pre-operative level (not improved)
= Single-stage; no second-look required
= Lifelong cavity cleaning + water precautions needed

Key requirement: Cholesteatoma MUST be confined to attic/mastoid
                Mesotympanum must be normal

Key steps:
1. Postauricular approach
2. Mastoidectomy → open antrum
3. Atticotomy → remove scutum, remove lateral canal wall
4. Eradicate ALL disease (attic, antrum, mastoid)
5. Preserve mesotympanum (do not enter it)
6. Low facial ridge + smooth saucerization
7. Meatoplasty (mandatory)

---

---

Thornwaldt (Tornwaldt) Cyst

---

Nomenclature

• Pharyngeal bursa cyst (Bursa pharyngea)
• Luschka's bursa cyst
• Nasopharyngeal bursa cyst

---

Definition

---

Embryology and Pathogenesis

Normal Embryology

• During early embryogenesis, the notochord (axial mesodermal structure that becomes the nucleus pulposus of intervertebral discs) makes transient contact with the endoderm of the pharyngeal roof
• This contact point is the pharyngeal bursa (Bursa pharyngea of Luschka) - a small pit or invagination in the roof of the nasopharynx, located in the midline between the longus capitis muscles
• Normally, this communication regresses completely by birth

Cyst Formation

• If this connection fails to regress, a residual pit or recess persists (the pharyngeal bursa)
• The opening of this bursa may become obstructed due to:
  • Infection
  • Adenoid hypertrophy
  • Trauma or surgery
  • Inflammatory scarring
• Obstruction traps secretions from the respiratory epithelial lining → progressive accumulation → cyst formation
• The cyst is lined by respiratory epithelium (pseudostratified ciliated columnar) and accumulates fluid with variable proteinaceous content
• Secondary infection causes inflammation and may change the cyst contents

Classification by Drainage

---

Epidemiology

---

Anatomy and Location

• Exact location: Posterior nasopharyngeal wall, strictly in the midline, between the two longus capitis muscles
• Sits in the roof (vault) of the nasopharynx, immediately superior to the pharyngeal tonsil (adenoid) region
• Lies immediately deep to the pharyngeal mucosa (submucosal)
• May be slightly off-midline in some cases
• Surrounded by the prevertebral muscles laterally
• Superior relation: basisphenoid and basiocciput (clivus)
• Posterior relation: anterior arch of atlas (C1)

---

Clinical Features

Asymptomatic (Majority)

• Most cysts are small (2-10 mm) and completely asymptomatic
• Discovered incidentally on MRI obtained for headache, sleep apnea evaluation, or other conditions
• Represent the majority of cases in imaging series

Symptomatic ("Tornwaldt's Disease")

"Symptomatic cysts may cause nasal obstruction, postnasal drip, halitosis, occipital headache, or Eustachian tube dysfunction."

• PMID 40677866 (Radiol Case Rep 2025)

"Smaller cysts are usually asymptomatic; cysts exceeding a diameter of 1 to 2 cm may be symptomatic."

• PMID 31760788 (Ear Nose Throat J)

---

Diagnosis

1. Nasal Endoscopy

• First-line investigation when clinical suspicion exists
• Reveals a smooth, submucosal, well-encapsulated midline mass on the roof/posterior wall of the nasopharynx
• Surface covered by intact normal nasopharyngeal mucosa (unless infected/ulcerated)
• The pharyngeal orifice of the bursa may be visible as a small pit, but is often difficult to see even when unobstructed
• Cannot assess depth, intracranial extension, or cyst content

2. MRI - Gold Standard Imaging

• Better soft tissue characterization (confirms cystic nature vs. solid mass)
• Can detect intracranial extension
• Differentiates from other nasopharyngeal pathology
• No radiation

• Low-attenuation (hypodense) soft tissue mass on the posterior nasopharyngeal wall
• Sharply defined margins
• No bony erosion or surrounding soft tissue reaction
• Helpful in differentiating from bony lesions

3. Histopathology

• Confirms diagnosis after surgical removal
• Cyst wall lined by respiratory epithelium (pseudostratified ciliated columnar) ± squamous metaplastic areas
• Variable content: clear/mucoid/proteinaceous fluid
• Inflammatory infiltrate if secondarily infected
• No malignant features

---

Differential Diagnosis

CRITICAL: Thornwaldt cysts must be differentiated from nasopharyngeal encephaloceles before any surgical excision. Inadvertent excision of an encephalocele can cause catastrophic CSF leak and meningitis.

---

Treatment

Asymptomatic Cysts

• No treatment required - conservative management with clinical observation
• Annual or biannual endoscopic follow-up if large
• Reassure patient of benign nature

Symptomatic Cysts - Surgical Options

1. Endoscopic Transnasal Marsupialization (Preferred)

• Treatment of choice for symptomatic Thornwaldt cysts
• Performed under general anaesthesia with a rigid nasal endoscope
• The cyst is opened widely (unroofed/marsupialised) so its contents drain freely into the nasopharynx
• The posterior wall of the cyst is excised, creating a wide opening
• Allows drainage and prevents re-accumulation
• Excellent outcomes - complete symptom resolution in the vast majority
• Low recurrence rate
• Successful treatment confirmed in both recent case series (PMID 38784350, Cureus 2024)

2. Complete Surgical Excision

• Complete cyst removal with its wall
• More technically demanding; risk of damage to prevertebral musculature
• Performed when marsupialization is insufficient or recurrence occurs
• Transnasal endoscopic approach

3. Aspiration/Drainage Alone

• Generally not recommended - high recurrence rate as the cyst wall remains intact

Post-operative

• Symptom resolution usually complete
• Low recurrence rate with adequate marsupialization
• Follow-up endoscopy at 3-6 months

---

Key Clinical Points

---

Summary Table

---

---

Sinonasal Undifferentiated Carcinoma (SNUC)

---

Definition

"SNUCs are rare tumors arising from Schneiderian epithelium and were only recognized as a distinct entity in 1986 [by Frierson et al.]"

• Cummings Otolaryngology Head and Neck Surgery

---

Historical Context

• First formally described as a distinct entity by Frierson et al. in 1986
• Also known as anaplastic carcinoma of the sinonasal tract
• Before 1986, many of these tumors were misclassified as olfactory neuroblastoma (ONB/esthesioneuroblastoma), lymphoma, or poorly differentiated squamous cell carcinoma
• Recent molecular/genomic studies (post-2015) have further subdivided the SNUC category into distinct molecular entities with different biology, prognosis, and treatment implications

---

Epidemiology

---

Molecular Subtypes - The Modern Classification

"Several additional tumor types with distinct pathologic and genomic features have been identified, including IDH2-mutant SNUCs, INI-1-deficient sinonasal carcinomas, and NUT-midline carcinomas."

• Cummings Otolaryngology

Molecular subtyping is now mandatory in pathological workup, as it has treatment and prognostic implications, and because clinical series that predate molecular classification may have mixed multiple distinct entities.

---

Pathology

Gross Appearance

• Large, bulky, polypoid or infiltrative mass
• Often fills the nasal cavity/sinus and extends beyond
• Areas of necrosis and hemorrhage common
• Paradoxically, often produces few symptoms despite extensive nature - patients may ignore early symptoms

Histology

• Sheets, nests, trabeculae, or ribbons of undifferentiated cells
• Small to medium-sized cells with high nuclear:cytoplasmic ratio
• Prominent nucleoli
• Abundant mitoses and geographic necrosis (characteristic feature)
• No squamous differentiation (no keratin pearls, intercellular bridges)
• No glandular differentiation (no mucin, no acinar structures)
• No neuroendocrine differentiation by light microscopy (though focal IHC staining may be present)
• Vascular and perineural invasion common

Immunohistochemistry (IHC) - Critical for Diagnosis

Key distinguishing feature: SNUC is typically EBV-negative, which separates it from undifferentiated nasopharyngeal carcinoma (WHO Type 3/lymphoepithelioma) - one of the most important and clinically critical distinctions.

---

Clinical Features

Symptoms

"It is a highly aggressive and invasive tumour commonly containing areas of necrosis but, paradoxically, often produces few symptoms despite its extensive nature."

• Scott-Brown's Otorhinolaryngology

Sites of Origin

• Nasal cavity (most common primary site)
• Ethmoid sinuses
• Maxillary sinus
• May involve multiple compartments simultaneously at diagnosis
• Skull base, cribriform plate, orbit, and anterior cranial fossa involvement common at presentation

---

Differential Diagnosis

---

Staging

80% of SNUCs are T4 at presentation - the most locally advanced stage. This is the fundamental driver of its poor prognosis.

---

Investigations

Imaging

Tissue Diagnosis

• Biopsy (endoscopic or open) - essential
• Full IHC panel including cytokeratins, neuroendocrine markers, S100, p40/p63, EBV, NUT, INI-1
• Molecular testing: IDH2, SMARCB1, NUTM1 FISH

---

Treatment

Principles

• Multimodality treatment is essential - single-modality treatment is strongly associated with worse survival
• Treatment must be individualized based on resectability, stage, molecular subtype, and patient fitness

Treatment Modalities

Surgery

• Radical surgical resection (craniofacial resection/anterior skull base surgery) when feasible
• Endoscopic skull base surgery increasingly used for selected cases
• Aims for R0 (clear margins) resection
• Combined open and endoscopic approaches for extensive disease
• 5-year local control of 74% with gross total resection vs. only 24% with subtotal resection (UCSF series)
• Elective or therapeutic neck dissection - considered given high regional failure rate (27% at 2 years)

Radiation Therapy

• IMRT (Intensity-Modulated Radiotherapy) is standard adjuvant/definitive modality
• Doses typically 60-70 Gy to primary site
• Particle therapy (proton beam, carbon ion) increasingly used for skull base proximity - better dose distribution, sparing of critical neural structures
• Elective nodal irradiation recommended given risk of regional recurrence

Chemotherapy

• Platinum-based regimens (cisplatin + 5-FU, or cisplatin + paclitaxel) are most commonly used
• Two roles:
  1. Induction (neoadjuvant) chemotherapy - given before surgery/RT to downstage tumor and test chemo-sensitivity
  2. Concurrent chemotherapy with radiation (chemoRT) - radiosensitization

Emerging Role of Induction Chemotherapy

Induction chemotherapy (IC) has recently gained major importance in SNUC management.

• 5-year OS with IC: 72.6% vs. 44.5% without IC
• "IC should be considered in every patient diagnosed with SNUC"

• Tests tumor chemo-sensitivity (good responders are selected for further aggressive local treatment)
• Potential to downstage unresectable disease to resectable
• Treats occult micrometastatic disease early
• Avoids unnecessary radical surgery in chemoresistant (poor prognosis) tumors

Evidence-Based Treatment Strategies

Key caveat: Direct comparisons are confounded by selection bias - unresectable tumors are treated with non-operative approaches, artificially worsening those outcomes.

Treatment Algorithm (General)

SNUC Diagnosis
    ↓
Molecular subtyping (IDH2, INI-1, NUT, SMARCA4)
    ↓
Staging (CT + MRI + PET-CT)
    ↓
Multidisciplinary tumor board
    ↓
Resectable disease:              Unresectable / borderline disease:
  ↓                                ↓
Induction chemotherapy           Induction chemotherapy
(cisplatin-based)                (cisplatin-based)
  ↓                                ↓
Responders → Surgery +          Good response → consider
adjuvant IMRT ± chemo            surgery or definitive CRT
  ↓
Non-responders → Definitive CRT

Molecular-Targeted Therapy (Emerging)

• IDH2-mutant SNUC: Enasidenib (IDH2 inhibitor) - case reports of response
• NUT carcinoma: BET bromodomain inhibitors (e.g., OTX015) - under investigation
• SMARCB1-deficient: EZH2 inhibitors (tazemetostat) - under investigation
• Immune checkpoint inhibitors - role being explored given tumor microenvironment data

---

Prognosis

• T stage (T4b worst)
• Extent of surgical resection (R0 vs R1/R2)
• Chemotherapy response (induction chemo responders do significantly better)
• Molecular subtype (IDH2-mutant may behave differently)
• Intracranial extension

---

Comparison with Related Entities

---

Summary

SNUC - Key Facts:
• Rare, aggressive, high-grade carcinoma; Schneiderian epithelium origin
• First described 1986; now subdivided by molecular markers
  (IDH2, INI-1/SMARCB1, NUT, SMARCA4)
• 80% present at T4; often paradoxically few symptoms despite large mass
• EBV-NEGATIVE (key feature distinguishing from undifferentiated NPC)
• Diagnosis of exclusion after ruling out SCC, NEC, melanoma, lymphoma, ONB

Treatment:
• NEVER single-modality
• Induction chemotherapy → dramatically improves OS (72.6% vs 44.5%)
• Surgery + adjuvant IMRT = best local control (74% if gross total resection)
• Definitive CRT for unresectable disease
• Elective neck treatment mandatory (27% regional failure at 2 years)
• Particle therapy (proton/carbon) for skull base proximity

Prognosis:
• 5-year OS ~40-65% with optimal multimodality treatment
• Significantly better with induction chemotherapy
• Distant metastases and locoregional recurrence are principal failure modes

---

---

Cernea Classification of the External Branch of the Superior Laryngeal Nerve (EBSLN)

---

Background

"In 1992, we proposed the following surgical anatomic classification of the EBSLN, based on the relationships among the nerve, the superior thyroid vessels, and the upper border of the superior thyroid pole."

• Cernea et al. (original description, via Entokey)

"The course of the external branch is variable and meticulous dissection close to the superior pole is necessary to prevent iatrogenic injury during thyroidectomy."

• Mulholland and Greenfield's Surgery: Scientific Principles and Practice, 7e

---

Anatomy Relevant to the Classification

The Superior Laryngeal Nerve (SLN)

• Arises from the inferior ganglion of the vagus nerve (CN X)
• Divides into two branches at the level of the hyoid bone:
  1. Internal branch (IBSLN): Sensory to the supraglottis and laryngeal mucosa above the vocal cords; enters the larynx through the thyrohyoid membrane
  2. External branch (EBSLN): Motor to the cricothyroid muscle (CTM); the branch classified by Cernea

The EBSLN

• Descends along the inferior pharyngeal constrictor muscle
• Runs in close proximity to the superior thyroid artery (STA) and superior thyroid vein (STV)
• Enters the cricothyroid muscle from its posteromedial surface
• The cricothyroid muscle is the only intrinsic laryngeal muscle innervated outside the larynx
• CTM function: tenses and elongates the vocal cord → raises vocal pitch, increases vocal projection and fundamental frequency

Why It Matters Surgically

• Cricothyroid muscle paralysis
• Loss of ability to produce high-pitched tones
• Lowered fundamental voice frequency
• Reduced vocal projection and endurance
• Vocal fatigue, especially during prolonged speaking or singing
• Often missed on routine laryngoscopy (cords look normal; only acoustic analysis or EMG detects the deficit)
• Particularly devastating for professional singers, teachers, lawyers, public speakers

---

The Cernea Classification

---

Type 1 (Safe Zone)

The nerve crosses safely above the level where the superior pole vessels are ligated. With careful high-vessel ligation at the thyroid capsule (hugging technique), injury is unlikely.

---

Type 2a (Intermediate Risk)

The nerve is close enough to be inadvertently clamped or ligated with the superior thyroid vessels if mass ligation is performed. Individual vessel ligation at the thyroid capsule reduces (but does not eliminate) risk.

---

Type 2b (Highest Risk)

The nerve is essentially hidden behind the superior pole, easily mistaken for a vascular structure, and at maximal risk during routine superior pole dissection and vessel ligation. A large goiter dramatically increases the likelihood of this configuration.

---

Type NI (Non-Identifiable)

• The nerve runs so deeply or under the pharyngeal constrictor that it cannot be visualized
• Some authors consider this a separate category; others fold it into Type 2b or attribute it to the Type 4 of the Kierner classification (nerve running dorsally)

---

Summary Table

Key insight: Large goiter shifts the classification distribution dramatically toward Type 2b (54% in large goiters vs. 14-20% in small goiters), because the enlarged gland physically displaces the EBSLN downward and medially relative to the superior pole vessels.

---

Comparison with Other Classifications

Kierner Classification (1998)

Friedman Classification

A 2023 prospective study (PMID 38075061) found the Friedman classification has higher accuracy (69.8% vs 44.3%) for predicting EBSLN injury risk than Cernea, though with a higher false-negative rate. All three classifications (Cernea 2a/2b, Kierner 2/3/4, Friedman 2) identify the same high-risk anatomical configurations.

---

Surgical Implications

The "Hugging" or "Capsular Dissection" Technique

• Ligate the superior thyroid vessels individually at the thyroid capsule rather than en masse high in the neck
• Minimizes the zone of dissection near the EBSLN regardless of its classification type
• Considered the single most important technical maneuver to protect the EBSLN

Identification Strategy Based on Classification

Intraoperative Neuromonitoring (IONM) for EBSLN

• EBSLN signal attenuation >50% after superior pole dissection correlates with significantly worse voice outcomes (PMID 33521945, Laryngoscope 2021)
• CTM needle electrodes provide finer amplitude measurement than standard ETT electrodes for detecting subtle EBSLN injury
• Cricothyroid muscle twitch on stimulation is visible in ~92.5% of cases; EMG signal obtained in ~54%

---

Clinical Consequences of EBSLN Injury

---

Key Points Summary

Cernea Classification - EBSLN (1992)

Type 1:  Crosses STV ≥1 cm ABOVE superior pole → LOW risk (~60% small goiter)
Type 2a: Crosses STV <1 cm ABOVE superior pole → MODERATE risk (~17%)
Type 2b: Crosses STV BELOW superior pole → HIGHEST risk (~20% small, ~54% large goiter)
NI:      Non-identifiable → ~3%

The "2" types (2a + 2b) are HIGH-RISK requiring active nerve identification

Large goiter → dramatically shifts distribution to Type 2b (54%)

Surgical principle: Individual capsular vessel ligation (hugging technique)
                   ± IONM to detect subtle injury
                   Active identification mandatory in Types 2a/2b and large goiters

EBSLN injury → cricothyroid palsy → loss of high pitch, vocal fatigue
→ Often MISSED on routine laryngoscopy

---

---

Epstein-Barr Virus (EBV) and Its Implications in ENT

---

The Virus - Overview

Key Virological Features

Lifecycle Phases

1. Primary infection - EBV enters via oropharyngeal epithelium, replicates, then infects B lymphocytes via CD21
2. B-cell immortalization - EBV drives polyclonal B-cell proliferation via latent gene expression (LMP1, LMP2, EBNAs)
3. Immune control - massive CTL (CD8+) response → atypical lymphocytes → controls acute infection
4. Latency - virus persists in resting memory B cells with minimal gene expression
5. Reactivation - during immunosuppression, stress; lytic replication resumes

EBV Latency Programs

---

EBV in ENT - Organ-by-Organ Overview

---

1. Infectious Mononucleosis (IM) - "Glandular Fever"

Pathogenesis

• Primary EBV infection in adolescents and young adults (15-24 years peak)
• In childhood infection: typically asymptomatic or mild
• In adolescence/adulthood: symptomatic IM in ~50% of primary infections
• Massive polyclonal B-cell proliferation → vigorous CTL response → atypical lymphocytes (Downey cells)
• The profound pharyngo-tonsillar inflammation is partly immunopathological (T-cell mediated)

Classic ENT/Clinical Triad

1. Exudative pharyngotonsillitis - severe, confluent white/grey exudate; can be membranous and simulate diphtheria
2. Cervical lymphadenopathy - posterior cervical chain predominance (vs. anterior in bacterial tonsillitis); bilateral; tender
3. Fever - high-grade, prolonged (1-3 weeks)

Additional Features

ENT-Specific Complications

1a. Airway Obstruction - The Most Critical ENT Emergency

• Occurs in up to 25% of hospitalized IM patients
• Mechanism: massive lymphoid hyperplasia throughout Waldeyer's ring (tonsils + adenoids + lymphoid tissue) + mucosal oedema
• Can be life-threatening
• Management:
  • Corticosteroids (dexamethasone/prednisolone) - first-line; reduces tonsillar oedema within hours
  • Humidified oxygen, nebulised adrenaline for severe cases
  • Acute tonsillectomy/adenotonsillectomy - when steroids fail; controversial but life-saving in extremis
  • Emergency tracheostomy - last resort for complete obstruction

1b. Peritonsillar Abscess (PTA)

• More common in IM than previously thought; some studies report >10% of IM cases develop PTA
• Bilateral PTA more prevalent in IM than in bacterial tonsillitis (EBV causes bilateral tonsillar hypertrophy + immune suppression → bacterial superinfection with Group A Strep, Fusobacterium, S. aureus)
• Mechanism: decreased mucosal antibody production → bacterial attachment to tonsillar epithelium
• Management: aspiration/incision & drainage + antibiotics (avoid amoxicillin - rash risk)
• CT neck mandatory if bilateral PTA or deep neck space infection suspected

1c. Deep Neck Space Infection

• Secondary to tonsillar/PTA spread
• Parapharyngeal / retropharyngeal abscess
• Risk of Lemierre's syndrome (septic thrombophlebitis of internal jugular vein), though more typically caused by Fusobacterium

1d. Otitis Media with Effusion (OME)

• Adenoid hypertrophy in IM → Eustachian tube obstruction → OME
• Usually resolves as IM resolves

Diagnosis of EBV-IM

EBV Serology Pattern

Treatment of IM

• Supportive - rest, analgesics (paracetamol, NSAIDs - avoid aspirin under 16 years), adequate hydration
• Avoid amoxicillin/ampicillin - causes maculopapular rash in ~90%
• Corticosteroids - indicated for: severe airway compromise, thrombocytopenia, haemolytic anaemia, severe hepatitis; NOT routine
• Antivirals (aciclovir) - minimal clinical benefit in uncomplicated IM; may be used in severe/immunocompromised
• Contact sports restriction - 3-4 weeks minimum due to splenic rupture risk
• Antiviral prophylaxis against secondary streptococcal infection - sometimes used

---

2. Nasopharyngeal Carcinoma (NPC)

Epidemiology and EBV Link

• EBV is found in virtually 100% of undifferentiated (WHO Type III) NPC cases
• Consistently associated by serology, EBER in situ hybridization, and EBV genome detection
• Endemic regions: Southern China (30-50 per 100,000/year; 20x higher than non-endemic populations), Southeast Asia, North Africa, Arctic Inuit populations
• Rare in the West (<1% of all cancers in the US)
• Bimodal age distribution: Peak in teenagers/young adults AND again in 50-60 year age group
• Male:Female ratio = 3:1

"Genetic susceptibility, tobacco smoking, early infection by EBV and consumption of traditional diets, particularly salted fish, are known to contribute."

• Bailey and Love's Short Practice of Surgery, 28th ed.

Aetiological Factors for NPC

EBV Oncogenic Mechanism in NPC

• LMP1 (Latent Membrane Protein 1) - acts as a constitutively active CD40 receptor mimic → activates NF-κB pathway → anti-apoptotic, pro-proliferative signals → oncogenesis
• LMP2 - PI3K/Akt pathway activation
• EBNA1 - maintains EBV episome in dividing cells
• EBERs (EBV-encoded RNAs) - non-coding RNAs; used for diagnostic EBER ISH staining
• miRBARTs - EBV-encoded microRNAs; target tumour suppressor genes

"The tumour cells contain EBV genomes and express several EBV proteins, including LMP1, which generates oncogenic signals that activate the NF-κB pathway."

• Robbins & Kumar Basic Pathology

WHO Histological Classification of NPC

Type III constitutes >90% of NPC in endemic areas; T-cell infiltrate is the immune response to EBV antigens.

Clinical Features of NPC

"In about 5% of patients, the nasopharynx may look normal or minimally asymmetrical but contains submucosal NPC." - Bailey & Love

Diagnosis

• Nasal endoscopy + biopsy - direct visualization; biopsy from lateral pharyngeal recess (fossa of Rosenmuller) most productive
• MRI - gold standard for extent, perineural spread, skull base, intracranial extension
• CT chest/abdomen - distant metastases
• PET-CT - nodal and distant staging
• EBV DNA (plasma) - highly sensitive/specific; used for screening, monitoring treatment response, predicting relapse
• EBER ISH - definitive histological confirmation of EBV in tumour cells
• EBV serology (VCA IgA, EA IgA) - elevated in NPC; used for population screening in endemic areas

Staging and Treatment

• IMRT local/locoregional progression-free rates: 95-98% (UCSF series)
• RTOG 02-25: excellent 2-year locoregional control of 90% in multi-institutional setting
• Induction TPF (docetaxel + cisplatin + 5-FU) before CRT: improved 3-year failure-free survival (80% vs 72%), OS (92% vs 86%)
• 5-year OS: 36-58% overall; stage I/II approaches 90%+; distant metastasis remains dominant failure mode (up to 30%)
• Circulating EBV DNA post-RT: indicates high relapse risk; guides adjuvant therapy decisions (NRG HN001 trial)
• Bevacizumab + CRT: feasibility demonstrated (RTOG 06-15)
• Immune checkpoint inhibitors (pembrolizumab, nivolumab): active in recurrent/metastatic NPC; EBV-specific T-cell responses make NPC potentially immunotherapy-sensitive

"Circulating EBV DNA after completion of RT appears to indicate a high risk of relapse."

• Cummings Otolaryngology

---

3. EBV-Associated Lymphomas with ENT Manifestations

3a. Burkitt Lymphoma

• EBV association: ~100% of African (endemic) Burkitt; ~20% of sporadic Burkitt
• Most common childhood malignancy in sub-Saharan Africa; often presents with jaw/facial bone involvement (classic "African" Burkitt)
• The jaw tumour - rapidly expanding lytic bone lesion of the mandible or maxilla - is the hallmark ENT manifestation
• Histology: "starry sky" appearance (macrophages engulfing apoptotic tumour cells)
• EBV latency I (EBNA1 only)
• t(8;14) translocation: MYC oncogene juxtaposed to IgH gene → constitutive MYC overexpression
• Treatment: intensive cyclophosphamide-based chemotherapy; excellent response

3b. Hodgkin Lymphoma

• EBV association: ~40-60% of mixed cellularity subtype; ~20% of nodular sclerosis subtype
• Reed-Sternberg cells contain EBV (Latency II: LMP1/LMP2 + EBNA1)
• Presents with cervical lymphadenopathy in ~70% - highly relevant to ENT
• Level II/III neck nodes most commonly involved
• "B symptoms": fever, night sweats, weight loss
• Requires excision biopsy for diagnosis (FNA insufficient)
• Treatment: ABVD chemotherapy ± RT

3c. NK/T-Cell Lymphoma (Lethal Midline Granuloma)

• EBV-positive in nearly 100% of cases (Latency II)
• Originates from NK cells or cytotoxic T cells
• Classic ENT presentation: Destructive midline facial/nasal lesion - ulceration and necrosis of the nasal septum, hard palate, midface
• Often mistaken for Wegener's granulomatosis (GPA) or fungal infection
• Diagnosis: biopsy (EBER ISH confirms EBV); CXCL9, CD56, granzyme B, TIA-1 positive
• Predominantly in Asia and Central/South America
• Treatment: non-anthracycline-based (L-ASPA regimens: SMILE protocol) + involved-field RT; poor prognosis if disseminated

3d. Post-Transplant Lymphoproliferative Disorder (PTLD)

• EBV latency III (all EBNAs + LMPs expressed due to absent T-cell immune control)
• Occurs in immunocompromised patients: solid organ transplant, haematopoietic stem cell transplant, HIV/AIDS
• In solid organ transplant: can manifest as tonsillar/Waldeyer's ring lymphoma or cervical lymphadenopathy
• Spectrum: early polyclonal hyperplasia → monomorphic DLBCL-like
• Treatment: reduce immunosuppression + rituximab ± chemotherapy

---

4. EBV and Other ENT-Relevant Conditions

4a. Chronic Active EBV Infection (CAEBV)

• Rare; defined as persistent EBV infection >3 months with tissue damage
• Elevated EBV DNA in blood + tissue
• Manifestations: chronic pharyngitis, lymphadenopathy, fever, hepatosplenomegaly, skin lesions (hydroa vacciniforme), hearing loss
• Can progress to NK/T-cell lymphoma
• Treatment: haematopoietic stem cell transplantation

4b. Oral Hairy Leukoplakia

• EBV lytic replication in lateral tongue epithelium
• White, corrugated, non-removable plaques on lateral border of tongue
• Classic marker of HIV infection/immunosuppression
• Also occurs in other immunosuppressed states
• Benign; does not transform malignantly
• Treatment: aciclovir/valaciclovir if symptomatic; resolves with antiretroviral therapy

4c. EBV and Sinonasal Disease

• SNUC (Sinonasal Undifferentiated Carcinoma): characteristically EBV-negative (important distinguishing feature from NPC)
• EBV positivity in sinonasal undifferentiated tumours should prompt re-classification as nasopharyngeal carcinoma or NK/T-cell lymphoma
• Sinonasal lymphomas: EBV-associated NK/T-cell lymphoma affects nasal cavity primarily

4d. Salivary Gland Lymphoepithelial Lesions

• Lymphoepithelial cysts and lesions of parotid gland can occur in EBV/HIV co-infection
• Benign lymphoepithelial lesion (BLEL) of parotid: bilateral parotid enlargement in HIV; EBV associated
• Differential from Sjögren's syndrome, lymphoma

---

5. EBV-Specific Diagnostic Tests Summary

---

6. ENT-Specific Implications Summary Table

---